Skip to main content

Table 1 Demographic and clinical data in the two study groups

From: Could early infusion of fish-oil-based lipid emulsion affect the need for intensive care in moderately diseased COVID-19 patients? A randomized clinical trial

Variables

Group C (n = 30)

Group L (n = 30)

P-value

Age (years)

61.50 ± 6.79

61.10 ± 6.56

0.817

Gender (m/f)

19/11 (63.3/36.7%)

21/9 (70.0/30.0%)

0.584

Weight (kg)

91.30 ± 7.01

91.47 ± 8.45

0.934

Height (cm)

168.03 ± 4.90

168.57 ± 4.94

0.676

Body mass index (kg/m2)

32.37 ± 2.48

32.22 ± 2.96

0.832

Smoking (No/Yes)

13/17 (43.3/56.7%)

14/16 (46.7/53.3%)

0.795

Co-existing diseases

NO

9 (30.0%)

8 (26.7%)

0.975

HTN

4 (13.3%)

3 (10.0%)

DM

2 (6.7%)

2 (6.7%)

DM and HTN

4 (13.3%)

3 (10.0%)

Other combined diseases

11 (36.7%)

13 (43.3%)

Oncology

0 (0.0%)

1 (3.3)

  1. Data are presented as mean ± standard deviation, number (percentage)
  2. HTN Hypertension, DM Diabetes mellitus
  3. Group C (standard enteral nutrition) and Group L (fish-oil-based intravenous lipid emulsion)
  4. P < 0.05 is considered statistically significant